PolyNovo (PNV) is a AU-listed Healthcare company in Medical - Devices with a market capitalization of A$656M, trading at A$0.95 on the ASX. This SniperIQ fundamentals page covers PolyNovo's valuation (P/E 66.4x, P/B 7.9x), profitability (net margin 7.2%), revenue (A
27M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapA$656M
P/E (TTM)66.4x
Net Margin7.2%
Revenue (FY25)A
27M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is PolyNovo's market cap?
PolyNovo (PNV) has a market capitalization of approximately A$656M, trading at A$0.95 on the ASX. Market cap moves with the live share price.
What is PolyNovo's P/E ratio?
PolyNovo's trailing twelve-month P/E ratio is 66.4x, with a price-to-book (P/B) of 7.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PolyNovo?
PolyNovo runs a net profit margin of 7.2%, a gross margin of 32.3%, and an operating margin of 2.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PolyNovo generate?
PolyNovo reported revenue of A
27M for fiscal year 2025, with net income of A
3M and earnings per share (EPS) of 0.0191. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PolyNovo pay a dividend?
PolyNovo does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PolyNovo financially healthy?
PolyNovo carries a debt-to-equity ratio of 0.38x and a current ratio of 3.03x, with a market beta of 1.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PolyNovo a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PolyNovo (PNV) the key facts are: market cap A$656M, P/E 66.4x, revenue A
27M, 52-week range 0.865-1.665. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PolyNovo's full fundamentals live
Get PolyNovo's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.